Symbols / RXRX
RXRX Chart
About
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.84B |
| Enterprise Value | 1.26B | Income | -715.54M | Sales | 43.69M |
| Book/sh | 2.13 | Cash/sh | 1.27 | Dividend Yield | — |
| Payout | 0.00% | Employees | 800 | IPO | — |
| P/E | — | Forward P/E | -3.02 | PEG | — |
| P/S | 42.12 | P/B | 1.66 | P/C | — |
| EV/EBITDA | -1.98 | EV/Sales | 28.90 | Quick Ratio | 4.39 |
| Current Ratio | 4.60 | Debt/Eq | 7.87 | LT Debt/Eq | — |
| EPS (ttm) | -1.84 | EPS next Y | -1.17 | EPS Growth | — |
| Revenue Growth | -80.20% | Earnings | 2026-02-25 | ROA | -42.04% |
| ROE | -91.06% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -33.28% | Profit Margin | 0.00% | Shs Outstand | 514.19M |
| Shs Float | 504.10M | Short Float | 33.69% | Short Ratio | 8.17 |
| Short Interest | — | 52W High | 9.74 | 52W Low | 2.98 |
| Beta | 0.95 | Avg Volume | 21.78M | Volume | 15.61M |
| Target Price | $7.00 | Recom | None | Prev Close | $3.41 |
| Price | $3.53 | Change | 3.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.00
Mean price target
2. Current target
$3.53
Latest analyst target
3. DCF / Fair value
$-7.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.53
Low
$3.00
High
$11.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | up | JP Morgan | Neutral → Overweight | $11 |
| 2025-09-11 | reit | Needham | Buy → Buy | $8 |
| 2025-07-08 | reit | Needham | Buy → Buy | $8 |
| 2025-06-16 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $5 |
| 2025-05-06 | main | Needham | Buy → Buy | $8 |
| 2025-04-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $8 |
| 2025-04-08 | reit | Needham | Buy → Buy | $11 |
| 2025-02-28 | main | Leerink Partners | Market Perform → Market Perform | $6 |
| 2025-02-06 | reit | Needham | Buy → Buy | $11 |
| 2025-01-08 | main | Keybanc | Overweight → Overweight | $10 |
| 2024-12-11 | reit | Needham | Buy → Buy | $11 |
| 2024-11-20 | reit | Needham | Buy → Buy | $11 |
| 2024-11-07 | reit | Needham | Buy → Buy | $11 |
| 2024-09-04 | main | Needham | Buy → Buy | $11 |
| 2024-09-03 | main | Jefferies | Hold → Hold | $6 |
| 2024-09-03 | main | Leerink Partners | Market Perform → Market Perform | $8 |
| 2024-08-09 | main | Needham | Buy → Buy | $16 |
| 2024-07-11 | main | Keybanc | Overweight → Overweight | $12 |
| 2024-06-25 | reit | Needham | Buy → Buy | $17 |
| 2024-05-10 | reit | Needham | Buy → Buy | $17 |
- Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Fri, 20 Feb 2026 22
- Recursion Pharmaceuticals Stock (RXRX) Opinions on Upcoming Earnings Report - Quiver Quantitative Sun, 22 Feb 2026 14
- Four investor conferences in March: where TechBio firm Recursion will appear - Stock Titan Mon, 23 Feb 2026 12
- Applied Digital, WeRide Stocks Drops. Blame Nvidia. - Barron's Wed, 18 Feb 2026 21
- A Look At Recursion Pharmaceuticals (RXRX) Valuation After Nvidia Exit And ARK Invest Share Purchase - simplywall.st Mon, 23 Feb 2026 19
- Recursion Pharmaceuticals stock falls after NVIDIA sells entire stake - Investing.com Wed, 18 Feb 2026 12
- Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts - Finviz Mon, 23 Feb 2026 19
- Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - The Motley Fool hu, 01 Jan 2026 08
- RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes hu, 18 Dec 2025 08
- $RXRX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative Fri, 20 Feb 2026 19
- Inside Recursion’s push for self-driving drug labs with NVIDIA AI - Stock Titan Mon, 23 Feb 2026 13
- Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? - Yahoo Finance Sat, 24 Jan 2026 08
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As Narratives Clash Over Fair Value - Yahoo Finance Mon, 23 Feb 2026 14
- Is The Exit Of Nvidia And Novo Holdings Altering The Investment Case For Recursion Pharmaceuticals (RXRX)? - simplywall.st hu, 19 Feb 2026 07
- The Bull Case For Recursion Pharmaceuticals (RXRX) Could Change Following Nvidia’s Exit And ARK’s Big Buy-In - Yahoo Finance Mon, 23 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40000 | 138400.0 | — | Sale at price 3.46 per share. | GIBSON CHRISTOPHER | Director | — | 2026-02-19 00:00:00 | D |
| 1 | 40000 | nan | — | — | GIBSON CHRISTOPHER | Director | — | 2026-02-19 00:00:00 | D |
| 2 | 13426 | 41352.0 | — | Sale at price 3.08 per share. | TAYLOR BEN R | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 526318 | — | — | Stock Award(Grant) at price 0.00 per share. | DAVID HALLETT | Officer | — | 2026-02-06 00:00:00 | D |
| 4 | 1703892 | — | — | Stock Award(Grant) at price 0.00 per share. | KHAN NAJAT | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
| 5 | 30346 | — | — | Stock Award(Grant) at price 0.00 per share. | GIBSON CHRISTOPHER | Director | — | 2026-02-06 00:00:00 | D |
| 6 | 470533 | — | — | Stock Award(Grant) at price 0.00 per share. | TAYLOR BEN R | Chief Financial Officer | — | 2026-02-06 00:00:00 | D |
| 7 | 40000 | 164800.0 | — | Sale at price 4.12 per share. | GIBSON CHRISTOPHER | Director | — | 2026-02-04 00:00:00 | D |
| 8 | 40000 | nan | — | — | GIBSON CHRISTOPHER | Director | — | 2026-02-04 00:00:00 | D |
| 9 | 220000 | 924000.0 | — | Sale at price 4.20 per share. | BORGESON BLAKE CHARLES | Director | — | 2026-02-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.01 | 0.00 | 0.00 |
| NormalizedEBITDA | -426.72M | -307.63M | -227.66M | -174.29M |
| TotalUnusualItems | 0.00 | 0.00 | -827.00K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -827.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -463.66M | -328.07M | -239.48M | -186.48M |
| ReconciledDepreciation | 36.49M | 24.40M | 11.76M | 8.40M |
| ReconciledCostOfRevenue | 45.24M | 42.59M | 48.27M | 0.00 |
| EBITDA | -426.72M | -307.63M | -227.66M | -175.12M |
| EBIT | -463.22M | -332.03M | -239.42M | -183.53M |
| NetInterestIncome | 14.19M | 19.02M | 6.20M | -2.88M |
| InterestExpense | 1.57M | 97.00K | 55.00K | 2.95M |
| InterestIncome | 15.76M | 19.12M | 6.25M | 73.00K |
| NormalizedIncome | -463.66M | -328.07M | -239.48M | -185.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -463.66M | -328.07M | -239.48M | -186.48M |
| TotalExpenses | 537.49M | 393.94M | 285.41M | 192.78M |
| TotalOperatingIncomeAsReported | -479.00M | -350.06M | -245.73M | -182.78M |
| DilutedAverageShares | 274.21M | 207.85M | 175.54M | 125.35M |
| BasicAverageShares | 274.21M | 207.85M | 175.54M | 125.35M |
| DilutedEPS | -1.69 | -1.58 | -1.36 | -1.49 |
| BasicEPS | -1.69 | -1.58 | -1.36 | -1.49 |
| DilutedNIAvailtoComStockholders | -463.66M | -328.07M | -239.48M | -186.48M |
| NetIncomeCommonStockholders | -463.66M | -328.07M | -239.48M | -186.48M |
| NetIncome | -463.66M | -328.07M | -239.48M | -186.48M |
| NetIncomeIncludingNoncontrollingInterests | -463.66M | -328.07M | -239.48M | -186.48M |
| NetIncomeContinuousOperations | -463.66M | -328.07M | -239.48M | -186.48M |
| TaxProvision | -1.13M | -4.06M | 0.00 | 0.00 |
| PretaxIncome | -464.79M | -332.13M | -239.48M | -186.48M |
| OtherIncomeExpense | 30.00K | -1.09M | 52.00K | -825.00K |
| OtherNonOperatingIncomeExpenses | 30.00K | -1.09M | 52.00K | 2.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | -827.00K | |
| OtherSpecialCharges | 827.00K | |||
| NetNonOperatingInterestIncomeExpense | 14.19M | 19.02M | 6.20M | -2.88M |
| InterestExpenseNonOperating | 1.57M | 97.00K | 55.00K | 2.95M |
| InterestIncomeNonOperating | 15.76M | 19.12M | 6.25M | 73.00K |
| OperatingIncome | -479.00M | -350.06M | -245.73M | -182.78M |
| OperatingExpense | 492.25M | 351.35M | 237.13M | 192.78M |
| OtherOperatingExpenses | -351.00K | -699.00K | -162.00K | -178.00K |
| ResearchAndDevelopment | 314.42M | 241.23M | 155.70M | 135.27M |
| SellingGeneralAndAdministration | 178.18M | 110.82M | 81.60M | 57.68M |
| GeneralAndAdministrativeExpense | 178.18M | 110.82M | 81.60M | 57.68M |
| OtherGandA | 178.18M | 110.82M | 81.60M | 57.68M |
| GrossProfit | 13.25M | 1.29M | -8.59M | 10.00M |
| CostOfRevenue | 45.24M | 42.59M | 48.27M | 0.00 |
| TotalRevenue | 58.49M | 43.88M | 39.68M | 10.00M |
| OperatingRevenue | 58.49M | 43.88M | 39.68M | 10.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 396.80M | 234.27M | 191.02M | 170.27M |
| ShareIssued | 396.80M | 234.27M | 191.02M | 170.27M |
| TotalDebt | 108.49M | 50.67M | 51.01M | 11.48M |
| TangibleBookValue | 550.05M | 374.94M | 483.70M | 540.75M |
| InvestedCapital | 1.06B | 464.58M | 486.44M | 543.66M |
| WorkingCapital | 526.80M | 344.97M | 469.55M | 488.06M |
| NetTangibleAssets | 550.05M | 374.94M | 483.70M | 540.75M |
| CapitalLeaseObligations | 81.05M | 49.53M | 50.37M | 10.76M |
| CommonStockEquity | 1.03B | 463.44M | 485.81M | 542.94M |
| TotalCapitalization | 1.05B | 464.54M | 486.34M | 543.57M |
| TotalEquityGrossMinorityInterest | 1.03B | 463.44M | 485.81M | 542.94M |
| StockholdersEquity | 1.03B | 463.44M | 485.81M | 542.94M |
| GainsLossesNotAffectingRetainedEarnings | -7.64M | 0.00 | 0.00 | -126.00K |
| OtherEquityAdjustments | -7.64M | -126.00K | ||
| RetainedEarnings | -1.43B | -967.62M | -639.56M | -400.08M |
| AdditionalPaidInCapital | 2.47B | 1.43B | 1.13B | 943.14M |
| CapitalStock | 4.00K | 2.00K | 2.00K | 2.00K |
| CommonStock | 4.00K | 2.00K | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 413.82M | 190.26M | 215.48M | 67.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 226.34M | 97.09M | 115.22M | 20.75M |
| OtherNonCurrentLiabilities | 4.73M | |||
| NonCurrentDeferredLiabilities | 135.34M | 52.58M | 70.26M | 10.78M |
| NonCurrentDeferredRevenue | 118.77M | 51.24M | 70.26M | 6.67M |
| NonCurrentDeferredTaxesLiabilities | 16.57M | 1.34M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 86.27M | 44.52M | 44.96M | 9.97M |
| LongTermCapitalLeaseObligation | 67.25M | 43.41M | 44.42M | 9.34M |
| LongTermDebt | 19.02M | 1.10M | 536.00K | 633.00K |
| CurrentLiabilities | 187.47M | 93.17M | 100.27M | 46.66M |
| CurrentDeferredLiabilities | 61.77M | 36.43M | 56.73M | 10.00M |
| CurrentDeferredRevenue | 61.77M | 36.43M | 56.73M | 10.00M |
| CurrentDebtAndCapitalLeaseObligation | 22.22M | 6.16M | 6.05M | 1.51M |
| CurrentCapitalLeaseObligation | 13.79M | 6.12M | 5.95M | 1.42M |
| CurrentDebt | 8.43M | 41.00K | 97.00K | 90.00K |
| OtherCurrentBorrowings | 8.43M | 41.00K | 97.00K | 90.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 50.85M | 22.89M | 20.43M | 11.74M |
| PayablesAndAccruedExpenses | 52.63M | 27.70M | 17.06M | 23.41M |
| CurrentAccruedExpenses | 31.02M | 23.75M | 12.47M | 20.59M |
| Payables | 21.61M | 3.95M | 4.59M | 2.82M |
| AccountsPayable | 21.61M | 3.95M | 4.59M | 2.82M |
| TotalAssets | 1.45B | 653.70M | 701.29M | 610.35M |
| TotalNonCurrentAssets | 734.33M | 215.56M | 131.47M | 75.63M |
| OtherNonCurrentAssets | 14.45M | 6.89M | 7.92M | 8.72M |
| NonCurrentDeferredAssets | 1.93M | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 1.93M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 484.73M | 88.50M | 2.11M | 2.19M |
| OtherIntangibleAssets | 335.86M | 36.44M | 1.31M | 1.39M |
| Goodwill | 148.87M | 52.06M | 801.00K | 801.00K |
| NetPPE | 233.21M | 120.17M | 121.45M | 64.72M |
| AccumulatedDepreciation | -62.67M | -44.87M | -30.11M | -18.74M |
| GrossPPE | 295.88M | 165.04M | 151.56M | 83.46M |
| Leases | 72.73M | 45.93M | 41.87M | 13.94M |
| ConstructionInProgress | 2.71M | 3.23M | 8.75M | 16.45M |
| OtherProperties | 193.08M | 93.76M | 80.78M | 33.08M |
| MachineryFurnitureEquipment | 27.36M | 22.13M | 20.16M | 20.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 714.27M | 438.14M | 569.81M | 534.72M |
| OtherCurrentAssets | 67.71M | 40.25M | 15.87M | 7.51M |
| RestrictedCash | 3.04M | 3.23M | 1.28M | 1.55M |
| Receivables | 49.17M | 3.09M | 2.75M | 9.09M |
| OtherReceivables | 49.17M | 3.09M | 2.75M | 9.06M |
| AccountsReceivable | 0.00 | 34.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 594.35M | 391.56M | 549.91M | 516.56M |
| OtherShortTermInvestments | 0.00 | 231.45M | ||
| CashAndCashEquivalents | 594.35M | 391.56M | 549.91M | 285.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -376.22M | -300.33M | -120.88M | -198.41M |
| RepaymentOfDebt | -4.44M | -766.00K | -90.00K | -12.80M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 300.42M | 128.09M | 143.71M | 462.90M |
| CapitalExpenditure | -17.05M | -12.55M | -37.36M | -39.80M |
| InterestPaidSupplementalData | 96.00K | 55.00K | 680.00K | |
| EndCashPosition | 603.02M | 401.43M | 559.11M | 295.35M |
| BeginningCashPosition | 401.43M | 559.11M | 295.35M | 267.17M |
| EffectOfExchangeRateChanges | -3.41M | 188.00K | -307.00K | 0.00 |
| ChangesInCash | 205.00M | -157.88M | 264.07M | 28.18M |
| FinancingCashFlow | 304.12M | 140.13M | 154.34M | 458.54M |
| CashFlowFromContinuingFinancingActivities | 304.12M | 140.13M | 154.34M | 458.54M |
| ProceedsFromStockOptionExercised | 8.14M | 12.81M | 10.72M | 8.44M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 300.42M | 128.09M | 143.71M | 462.90M |
| CommonStockIssuance | 300.42M | 128.09M | 143.71M | 462.90M |
| NetIssuancePaymentsOfDebt | -4.44M | -766.00K | -90.00K | -12.80M |
| NetLongTermDebtIssuance | -4.44M | -766.00K | -90.00K | -12.80M |
| LongTermDebtPayments | -4.44M | -766.00K | -90.00K | -12.80M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 260.06M | -10.23M | 193.25M | -271.74M |
| CashFlowFromContinuingInvestingActivities | 260.06M | -10.23M | 193.25M | -271.74M |
| NetInvestmentPurchaseAndSale | 0.00 | 480.00K | 230.61M | -231.95M |
| SaleOfInvestment | 0.00 | 480.00K | 230.61M | 69.19M |
| PurchaseOfInvestment | 0.00 | 0.00 | -301.14M | |
| NetBusinessPurchaseAndSale | 277.10M | 1.84M | 0.00 | 0.00 |
| SaleOfBusiness | 277.10M | 1.84M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -3.35M | -597.00K | -300.00K | 0.00 |
| PurchaseOfIntangibles | -3.35M | -597.00K | -300.00K | 0.00 |
| NetPPEPurchaseAndSale | -13.70M | -11.96M | -37.06M | -39.80M |
| PurchaseOfPPE | -13.70M | -11.96M | -37.06M | -39.80M |
| OperatingCashFlow | -359.17M | -287.78M | -83.52M | -158.61M |
| CashFlowFromContinuingOperatingActivities | -359.17M | -287.78M | -83.52M | -158.61M |
| ChangeInWorkingCapital | -38.00M | -50.26M | 104.92M | -306.00K |
| ChangeInOtherWorkingCapital | -28.04M | -41.08M | 110.32M | -10.00M |
| ChangeInOtherCurrentLiabilities | -15.58M | -9.86M | -7.11M | 0.00 |
| ChangeInPayablesAndAccruedExpense | 11.69M | 8.44M | 1.71M | 15.07M |
| ChangeInAccruedExpense | 5.25M | 9.42M | -54.00K | 13.32M |
| ChangeInPayable | 6.43M | -987.00K | 1.77M | 1.75M |
| ChangeInAccountPayable | 6.43M | -987.00K | 1.77M | 1.75M |
| ChangeInReceivables | -6.07M | -7.76M | -2.00K | -5.38M |
| ChangesInAccountReceivables | 114.00K | |||
| OtherNonCashItems | 24.20M | 11.45M | 8.56M | 4.10M |
| StockBasedCompensation | 81.69M | 53.50M | 27.91M | 14.84M |
| AssetImpairmentCharge | 108.00K | 1.19M | 2.81M | 0.00 |
| DepreciationAmortizationDepletion | 36.49M | 24.40M | 11.76M | 8.40M |
| DepreciationAndAmortization | 36.49M | 24.40M | 11.76M | 8.40M |
| OperatingGainsLosses | 827.00K | |||
| NetIncomeFromContinuingOperations | -463.66M | -328.07M | -239.48M | -186.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RXRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|